Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial

Journal of Clinical Oncology

Volumn 10, Issue 7, 1992, Pages 1112-1118

  Rougier, Philippe ^b   Loplonche, Agnès ^b   Huguier, Michel ^b   Hay, Jean M ^b   Ollivier, Jean M ^b   Escat, Jean ^b   Salmon, Remy ^b   Julien, Michel ^b   Audy, Jean Claude Roullet ^b   Gallot, Denis ^b   Gouzi, Jean L ^b   Pailler, Jean Louis ^b   Elisa, Dominique ^b   Lacaine, François ^b   Roos, Stephen ^b   Rotman, Nelly ^b   Luboinski, Monique ^b   Lasser, Philippe ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HEPATIC ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE;

COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; HEPATIC ARTERY; HUMAN; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0026625223     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.7.1112     Document Type: Article

References (38)

1. Hill C, Benhamou E, Doyon F, et al: Evolution de la mortalité par cancer en France 1950-1985. Paris, France, 1989, Ed Inserm, p 93
2. Kemeny N: The systemic chemotherapy of hepatic metastases. Semin Oncol 10:148-158, 1983
3. Adson MA, Van Heerden JA, Adson MU, et al: Resection of hepatic metastases from colorectal cancer. Arch Surg 119:647-650, 1984
4. Fortner JG, Silva JS, Golbey RB, et al: Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 99:306-316, 1984
5. Foster HJH, Berman MM: Solid liver tumors, in Ebert PA (ed): Major Problems in Clinical Surgery, vol 22. Philadelphia, PA, WB Saunders, 1977, pp 209-234
6. Ensminger WD, Gyves JW: Regional chemotherapy of neoplastic diseases. Pharmacol Ther 21:277-293, 1983
7. Breedis C, Young C: The blood supply of neoplasm in the liver. Am J Path 30:969-974, 1954
8. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498-504, 1984
9. Lokich JJ, Ahlgren JD, Gull JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
10. Balch CM, Urist MM, Soong SJ, et al: A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 198:567-573, 1983
11. Niederhuber JE, Ensminger W, Gyves J, et al: Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53:1336-1343, 1984
12. Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 36:675-682, 1975
13. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
14. Daly JM, Kemeny N, Oderman P, et al: Long-term hepatic arterial infusion chemotherapy. Arch Surg 119:936-941, 1984
15. Elias D, Lasser Ph, Rougier Ph: A simplified surgical technique procedure for intraarterial chemotherapy in secondary liver cancer. Experience in 50 patients. Eur J Surg Oncol 13:441-448, 1987
16. Kaplan WD, Ensminger WD, Come SE, et al: Radionuclide angiography to predict patient response to hepatic artery chemotherapy. Cancer Treat Rep 64:1217-1222, 1980
17. Kemeny N, Daly J, Oderman P, et al: Hepatic artery pump infusion: Toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2:595-600, 1984
18. Buroker TR, Moertel CG, Fleming TR, et al: A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 3:1624-1631, 1985
19. Kaplan EL, Meier P: Nonparametric estimations for incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Rothman KJ: Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 31:557-560, 1978
21. Peto E, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I: Introduction and design. Br J Cancer 34:585-612, 1976
22. Peto E, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 35:1-39, 1977
23. Cox DR: Regression models and life-tables. J R Statist Soc (B) 34:187-220, 1972
24. Gail HG: Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. Cancer Treat Rep 69:1107-1112, 1985
25. Kemeny MM, Battifora H, Blayney DW, et al: Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 202:176-181, 1985
26. Stagg RJ, Lewis BJ, Chase J, et al: Alternating hepatic intraarterial (IA) ftoxuridine (FUDR) and IA 5-fluorouracil (5-FU) for colorectal cancer metastatic to the liver: A rational approach to prolong the benefit of IA fluoropyrimidine therapy by minimizing biliary and systemic toxicity. Proc Am Soc Clin Oncol 7:99, 1988 (abstr)
27. Hottenrott C, Lorenz M: Kann das auftreten extrahepatischer metastasen unter einer regionalen chemotherapie der leber durch eine zusätzliche systemische chemotherapie verhindert werden? Eine randomisierte multicenter-studie. Verh Bd 24:199-201, 1989
28. Safi F, Bittner R, Roscher R, et al: Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer 64:379-387, 1989
29. Hohn DC, Melnick J, Stagg RJ, et al: Biliary sclerosis in patients receiving hepatic arterial infusion of floxuridine. J Clin Oncol 3:98-102, 1985
30. Grage TB, Vassipoulos PP, Shingleton WW, et al: Results of a prospective randomized study of hepatic artery infusion with 5 fluorouracil versus intravenous 5 fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study. Surgery 86:550-555, 1979
31. Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5 fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685-693, 1987
32. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 7:1646-1654, 1989
33. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of flurodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459-465, 1987
34. Roemeling R, Grage T, Hrushesky WJM: Circadian modified intraarterial treatment of colorectal carcinoma metastatic to the liver allows higher dose intensity to be safely given. Proc Am Soc Clin Oncol 8:105, 1989 (abstr)
35. Martin JK, O'Connell M, Wieand HS, et al: Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 125:1022-1027, 1990
36. Kemeny N, Niedzwiecki D, Shurgot B, et al: Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment. Cancer 63:742-747, 1989
37. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
38. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1417, 1989